Find clinical trials for Ovarian Cancer in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma

Cancer

Carcinoma

Endometrial Cancer

Fallopian Tube Cancer

Breast Cancer

Triple Negative Breast Cancer

Ovarian Cancer trials near Charlotte, NC, USA:

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objecti ...

Enrolling

Primary Peritoneal Cancer

Platinum-refractory Ovarian Cancer

Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin

Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin

Phase 3

•

Genelux

Charlotte, North Carolina, United States and 29 other locations

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting

Advanced Ovarian Cancer

FIGO Stage III-IV

Drug: Olaparib 300mg tablets

Phase 3

•

AstraZeneca

Charlotte, North Carolina, United States and 176 other locations

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling

Low Grade Serous Ovarian Cancer

Drug: Defactinib

Drug: Letrozole

Phase 3

•

Verastem

Charlotte, North Carolina, United States and 84 other locations

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular ...

Active, not recruiting

Ovarian Neoplasms

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

Drug: Dostarlimab-Placebo

Drug: Standard of care

Phase 3

•

Tesaro

Charlotte, North Carolina, United States and 179 other locations

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors...

Enrolling

Solid Tumor

Breast Cancer

Drug: SON-DP

Phase 1

•

Qurgen

Huntersville, North Carolina, United States of America and 4 other locations

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the investigator. The hypotheses are that pembro...

Active, not recruiting

Carcinoma, Ovarian Epithelial

Fallopian Tube Neoplasms

Drug: Bevacizumab

Biological: Pembrolizumab

Phase 3

•

Merck Sharp & Dohme (MSD)

Charlotte, North Carolina, United States and 186 other locations

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET)

treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollme...

Active, not recruiting

Ovarian Cancer

Drug: Giredestrant

Drug: Cyclophosphamide

Phase 2

•

Roche

Charlotte, North Carolina, United States and 38 other locations

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01)

Dose (RP2D) in patients with ovarian cancer, and Part C will evaluate combination treatment of INX-315 plus a CDK4/6i and selectiv...

Enrolling

Metastatic Cancer

Advanced Cancer

Drug: INX-315

Drug: Fulvestrant

Phase 1, Phase 2

•

Incyclix Bio

Charlotte, North Carolina, United States and 6 other locations

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

of CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult patients with advanced solid tumors...

Active, not recruiting

Solid Tumor

Drug: CPO-100

Phase 1

•

Conjupro Biotherapeutics

Huntersville, North Carolina, United States of America and 7 other locations